Long-term durability of transcatheter aortic valve prostheses by Blackman, Daniel J et al.
Long­term durability of transcatheter aortic valve prostheses
Article  (Accepted Version)
http://sro.sussex.ac.uk
Blackman, Daniel J, Saraf, Smriti, MacCarthy, Philip A, Myat, Aung, Anderson, Simon G, Malkin, 
Christopher J, Cunnington, Michael S, Somers, Kathryn, Brennan, Paul, Manoharan, Ganesh, 
Parker, Jessica, Aldalati, Omar, Brecker, Stephen J, Dowling, Cameron, Hoole, Stephen P et al. 
(2019) Long-term durability of transcatheter aortic valve prostheses. Journal of the American 
College of Cardiology, 73 (5). pp. 537-545. ISSN 0735-1097 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/84037/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
Full Title: Long-term Transcatheter Aortic Valve Durability: Data from the UK TAVI 
Registry 
 
First Author: Blackman 
 
Short Title: Long-term Transcatheter Aortic Valve Durability 
 
Disclosures:  
Daniel J Blackman: Consultant and Proctor for Medtronic and Boston Scientific 
Philip MacCarthy: Proctor for Edwards LifeSciences, Research support from Boston Scientific, 
Consultancy/speaker fees from Abbott Vascular.  
Stephen Hoole: Research grant - Abbott Vascular Speaker bureau / Ad board Honoraria - 
Abbott Vascular and Boston Scientific  
Stephen Brecker : Grant Support / Consultant- Medtronic , Boston Scientific  
Adrian Banning: Institutional grant from Boston scientific to fund fellowship, Speaker fees 
Medtronic, Boston, Phillips, Abbott  
Michael Cunnington: Consulting fees for Boston Scientific  
Simon Kennon: Grant support Edwards, Medtronic and Boston  
Cameron Dowling: Grant support and speaker honoraria from Medtronic.  
Mark Spence: TAVI Proctor / Consultant / Research grant - Edwards Lifesciences, Boston 
Scientific and Medtronic  
Christopher Malkin: Proctor for Medtronic and Boston Scientific  
Sagar N.Doshi: Proctor and Consultant for Edwards Lifesciences 
David Hildick-Smith : Proctor for Boston Scientific and Medtronic  
 
 
 2 
First Author: Daniel J Blackman MD 
Other Authors: See Authors at end of manuscript 
For Correspondence:- 
Dr Daniel J Blackman 
Department of Cardiology 
Leeds General Infirmary 
Great George Street 
Leeds 
LS1 3EX 
United Kingdom 
E mail Daniel.blackman1@nhs.net 
Telephone: +44 113 392 2650 
Fax: +44 113 392 6435 
Total word count: 4713 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
ABSTRACT 
 
Background: Very little is known about long-term valve durability after trans-catheter aortic 
valve implantation (TAVI).  
 
Objectives: To evaluate the incidence of structural valve degeneration 5 to 10 years post-
procedure.  
 
Methods: 
Demographic, procedural, and in-hospital outcome data on patients who underwent TAVI from 
2007-2011 were obtained from the UK TAVI Registry. Patients in whom echocardiographic data 
were available both at baseline and ≥5 years post-TAVI were included. Haemodynamic 
structural valve degeneration (SVD) was determined according to European task force 
committee guidelines. 
 
Results:  
241 patients (79.3±7.5 years; 46.4% female) with paired post-procedure and late 
echocardiographic follow-up (median 5.8 years, range 5 - 10 years) were included. 150 patients 
(64.1%) were treated with a CoreValve and 80 (34.2%) with an Edwards valve. Peak aortic 
valve gradient at follow-up was lower than post-procedure (17.2 vs 19.4 mmHg, p=0.003). More 
patients had none/trivial aortic regurgitation (AR) at follow-up (47.4% vs 32.9%, p=0.055), and 
fewer had mild AR (41.7% vs 57.7%, p=0.02). There was 1 case (0.4%) of severe SVD 5.3 
years after implantation (new severe AR). There were 21 cases (8.7%) of moderate SVD (mean 
6.1 years post-implantation; range 4.9- 8.6 years). 12 of these (57%) were due to new AR and 9 
(43%) to restenosis.  
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Conclusions:   
Long-term transcatheter aortic valve function is excellent. In our study, 91% of patients 
remained free of structural valve deterioration between 5 and 10 years post-implantation. The 
incidence of severe structural valve degeneration was less than 1%. Moderate structural valve 
degeneration occurred in one in twelve patients. 
 
 
CONDENSED ABSTRACT 
This study evaluated long-term valve function and the incidence of structural valve degeneration 
(SVD) 5 to 10 years post-procedure using data from the UK TAVI Registry. 241 patients were 
included; 150 treated with a CoreValve and 80 with an Edwards valve. Long-term valve function 
was excellent, with no significant increase in average peak gradient or the incidence of 
moderate or worse aortic regurgitation. There was only 1 case of severe SVD (new severe AR), 
and moderate SVD was seen in one in twelve patients (21 cases (8.7%), 12 new AR; 9 
stenosis).   
 
 
  
 5 
INTRODUCTION 
Trans-catheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic 
valve replacement (SAVR) for the treatment of severe aortic stenosis. However, there are very 
few data regarding long-term valve durability. Assessments of valve function in the early 
randomised trial cohorts and registries have consistently shown preserved valve function up to 5 
years after TAVI 3-7. However, it is well recognised that structural valve degeneration (SVD) with 
surgical aortic valve bioprostheses is usually not seen until 5-10 years post-procedure, and data 
in this time-frame following TAVI are very sparse. There is a pressing need for greater 
understanding of the long-term durability of TAVI valves, particularly as TAVI moves into lower-
risk cohorts. The purpose of this study was to evaluate long-term valve function and to 
determine the incidence of haemodynamic structural valve degeneration between 5 and 10 
years after TAVI using data from the UK TAVI Registry1.  
 
METHODS 
 
Study population 
The UK TAVI Registry is a prospective mandatory database that includes all patients 
undergoing TAVI in the United Kingdom. Data are managed by the National Institute for 
Cardiovascular Outcomes Research (NICOR). Detailed information about the nature of the 
database has been published previously1. For the purposes of this study anonymised 
demographic, procedural, and in-hospital outcome data on all patients who underwent TAVI in 
the UK from 2007-2011 were obtained from the UK TAVI registry database.  Centres were 
asked to cross-reference their patients with the anonymised NICOR dataset using parameters 
such as date of procedure, age, gender, and serum creatinine, in order to allow access to 
clinical outcome and echocardiographic follow-up data not included in the UK TAVI registry.  
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Data collection 
Demographic, procedural, and in-hospital outcome data were generated from the UK TAVI 
registry database. Vital status was determined using the NHS Spine mortality database. 
Baseline echocardiographic data were obtained from the first transthoracic echocardiogram 
(TTE) performed after the TAVI procedure, no more than 6 months after valve implantation. 
Follow-up echocardiographic data were derived from the most recent TTE, no less than 4 years 
6 months post-TAVI.  
 
 
Definitions  
The definition of haemodynamic SVD was adapted from the European task force committee 
guidelines2 to include peak velocity to define SVD where mean gradient was not recorded, 
reflecting common practice in the UK. Definitions were as follows: Severe SVD: (i) mean 
gradient ≥40 mmHg and/or ≥20 mmHg increase from baseline AND/OR (ii) peak velocity ≥4m/s 
and/or ≥2m/s increase from baseline AND/OR (iii) severe new or worsening intra-prosthetic 
aortic regurgitation. Moderate SVD: (i) mean gradient ≥20 and <40 mmHg and/or ≥10 and 
<20 mmHg increase from baseline AND/OR (ii) peak velocity ≥3 and <4 m/s and/or ≥1.5 and <2 
m/s increase from baseline AND/OR (iii) moderate new or worsening intra-prosthetic aortic 
regurgitation.  
 
Statistical analyses  
Data were analysed using the statistical package Intercooled Stata version 14.2 (StataCorp, 
College Station, TX, USA). Data are expressed as mean (95% CI), mean (SD), median (range), 
or percentage where relevant. We used the χ2 test or Fisher’s exact test to compare categorical 
variables, and t tests or ANOVA for comparing continuous variables.  
 
 7 
Ethics 
Data were collected as part of a mandatory UK national cardiac audit and all patient-identifiable 
fields were removed prior to analysis. Ethical approval for the study was obtained from the UK 
Health Research Authority (HRA). 
 
RESULTS  
Study Population 
Of the 22 centres that had undertaken TAVI procedures between 2007 and 2011, 15 centres 
agreed to participate in the study. Paired echocardiographic data both at baseline and ≥4.5 
years post-TAVI were available in 241 patients – these patients formed the study population.  
130 (53.6%) were male; mean age was 79.3±7.5 years.  Mean Logistic Euro SCORE (LES) was 
19.9% (95% CI: 18.4 - 21.6). Baseline characteristics are summarized in Table 1.  
Procedural characteristics and outcomes 
Procedural characteristics and in-hospital outcomes are shown in Tables 2 and 3. TAVI was 
undertaken for treatment of pure aortic stenosis in 91.4% of patients, and for degeneration of a 
surgical valve in 6.8%. 150 patients (64.1%) were treated with the CoreValve system 
(Medtronic, Minneapolis, MN), 80 (34.2%) with an Edwards valve (SAPIEN/SAPIEN XT 
(Edwards Lifesciences, Irvine, CA)), 4 (1.7%) with Portico (Abbott Vascular, Minneapolis, MN) 
and in 8 patients the valve type was not recorded. The access route was transfemoral in the 
majority (80.4%); the remaining 19.6% were performed via the subclavian, transaortic, or 
transapical route. 73.6% of the procedures were done under general anaesthesia (Table 2). 
Valve deployment was successful in 97.4% of cases.  
 
Echocardiographic data 
Median echocardiographic follow-up was 5.8 years (IQR: 5.3 – 7.7 years). Follow-up extended 
to 6 years (n=168; 69%); 7 years (n=68; 28%); 8 years (n=30; 12%), 9 years (n=9; 4%) and 10 
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years (n=2; 1%). Echocardiographic data at baseline and long-term follow-up are shown in 
Table 4.  All 241 patients had baseline studies <6 months post-TAVI and at follow-up at least 
4½ years post-TAVI. Peak gradient was lower at follow-up compared to baseline (17.2 vs 19.4 
mmHg, p=0.003). More patients had none/trivial aortic regurgitation (AR) at follow-up (47.8% vs 
32.9%, p=0.055), and fewer had mild AR (41.7% vs 57.7%, p=0.02) compared to baseline.  
There was no change in the incidence of moderate AR. One patient (0.4%) developed new 
severe AR at follow-up.  
Echocardiographic data according to valve type 
Baseline and follow-up data according to valve type are shown in Table 5 and Figures 1-2. 
Amongst patients treated with the CoreValve prosthesis, peak gradient at follow-up was 
significantly lower than at baseline (15.2 vs 19.3 mmHg, p<0.0001), while there was no 
difference for the Edwards valve (19.8 vs 21.5 mmHg, p=0.29). CoreValve patients also 
demonstrated a significant reduction in the frequency of mild AR at follow-up (44.3% vs 69.9%, 
p=0.001) and a corresponding increase in none/trivial AR (46.3% vs 22.1%, p=0.02) For the 
Edwards valve there was no change in the proportion of patients with mild AR over time (33.3% 
vs 32.6%, p=0.98). The frequency of moderate AR was unchanged from baseline to follow-up 
with both valve types. 
 
Structural valve degeneration 
Severe SVD 
One patient who was treated with a 26mm CoreValve developed severe SVD with severe 
valvular aortic regurgitation 5 years and 4 months post-implantation. Her baseline 
echocardiogram showed mild paravalvular AR only. There were no features to suggest aortic 
endocarditis and she was not considered fit for further intervention.   
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Moderate SVD 
There were 21 cases (8.7%) of moderate SVD. 12 of these were due to new moderate aortic 
regurgitation, and 9 were due to an increased transvalvular gradient. Deterioration of the valve 
was noted at a median duration of 6 years 1 month (range 4 years 11 months to 8 years 7 
months) 13 (62%) of these patients were treated with the CoreValve, and 8 (38%) with an 
Edwards valve.  
 
 
No SVD 
In the substantial majority of patients (n=220; 90.9%) there was no structural valve deterioration 
of note. The Kaplan-Meier curves for survival free of severe and moderate SVD is shown in 
Figure 3. 
 
DISCUSSION 
The principal findings of this study are as follows: 1) Overall long-term function of trans-catheter 
aortic heart valves was excellent, with no increase in average peak gradient, and a reduction in 
aortic regurgitation at long-term follow-up. 2) Structural valve degeneration was very rare, with 
only 1 case of severe haemodynamic SVD (0.4%), and 21 cases of moderate SVD (8.7%). 3) 
The CoreValve prosthesis was associated with a fall in peak gradient from baseline to follow-up, 
and a change in the degree of AR from mild to none/trivial. 
Existing Data on TAVI Valve Durability 
Medium-term (≤ 5 years) 
There is now a significant body of randomised and registry data indicating good overall function 
of trans-catheter aortic valves up to 5 years, with a very low incidence of SVD. The Placement 
of Aortic Trans-catheter Valves (PARTNER) 1 trial randomised 699 patients with severe AS to 
either TAVI with the balloon-expandable SAPIEN valve or SAVR. No patients in either arm 
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demonstrated any evidence of SVD at 5 years follow up8. In a pooled analysis of 3 European 
trials: REVIVE II, TRAVERCE, and PARTNER EU, 410 patients were treated with the SAPIEN 
valve and no cases of SVD were identified9 .In the CoreValve Advance study, 996 patients had 
TAVI using the CoreValve prosthesis. Echocardiographic data were available on 860 patients 
with a mean follow up of 36.0 ± 21.1 months, with 267 patients having follow-up through 5 years. 
SVD was noted in 0.2% at 1 year, and 0.9% of patients at 5 years10. A recent review of nearly 
14,000 cases using multiple valve types found survival at 5 years to be 48% and at 7 years 
28%11, and another review of 8914 patients with a median follow-up between 1.6 and 5 years, 
reported an incidence of SVD post-TAVI up to 1.34 per 100 patient years. The pooled incidence 
of SVD in both studies was 28.08 per 10 000 patients/year (95% CI 2.46 - 73.4 per 100 patient 
years), and 12% of these patients underwent valve re-intervention12.In the Nordic aortic valve 
intervention (NOTION) trial, which compared TAVI vs. SAVR in 280 low risk patients (STS 
SCORE < 4%) with severe AS, the incidence of SVD at 5 years in patients treated with TAVI 
was significantly lower than patients treated surgically  (3.9 vs. 26.1%, p<0.0001)13.  
Long-term durability (> 5 years) 
Data from surgical bioprostheses have consistently shown that structural valve degeneration is 
rare in the first 5 years after surgery, but that failure occurs increasingly thereafter. Currently 
very few data exist describing TAVI valve function beyond 5 years. To our knowledge we have 
described the largest cohort of patients with echocardiographic assessment of valve function 
between 5 and 10 years, with data on 242 patients at 5 years, 168 at 6 years, 68 at 7 years, and 
30 at 8 years. We found an incidence of severe SVD of less than 0.5% at a median follow-up of 
5.8 years, with moderate SVD in 8.7%. 
Webb et al reported data on 236 patients who underwent TAVI between 5 and 10 years 
previously, and demonstrated severe structural valve degeneration, classified as severe 
stenosis, regurgitation, or re-intervention for SVD, in only 5 patients (1.9%)14. However, only 68 
patients were alive at 4 years, 41 at 6 years, and 8 at 8 years post-TAVI. Eltchaninoff described 
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findings in 242 patients treated more than 5, and up to 14 years previously15.  1 patient required 
re-intervention for severe SVD, while 4 in total had moderate or severe SVD. Again, numbers at 
risk beyond 5 years were small - only 17 at 6 years and 1 at 8 years. Testa et al16 presented 
data on 2343 patients who underwent TAVI at 13 Italian centres between June 2007 and 
December 2016. All patients received the Core Valve or Evolut R system. Mean duration of 
follow up was 22 months, with a very small number of patients having follow up to 9 years. The 
total number of cases of severe SVD was extremely low, seen in only 3 patients at 26, 72 and 
89 months respectively. 
 
Surgical Valve Durability  
Understanding of surgical valve durability has been hampered by the absence of standardized 
definitions of structural valve degeneration. Most studies have reported SVD in terms of the 
need for re-operation. Puri and colleagues reported that SVD in surgical bioprostheses tends to 
be seen about 8 years post-surgery, and rapidly increases in frequency after 10 years17. Current 
data suggest an incidence of SVD (defined as death, re-operation or clinical reinvestigation due 
to suspected SVD) of less than 1% before 5 years, increasing to 10% at 10 years for patents 
>65 years age18. However, the incidence and timing of SVD is highly dependent on the type of 
prosthesis used, with time to SVD being reported as early as 3.8+/- 1.4 years for the Sorin 
Mitroflow prosthesis19; and as late as 19 years for the Carpentier-Edwards Perimount (Edwards 
Lifesciences) valve20. Freedom from SVD has been reported to be 95% for the Trifecta valve (St 
Jude) 21 at 6 years, and 95% for the Hancock II valve (Medtronic) at 10 years22. Pibarot reported 
overall freedom from re-intervention or death in surgical valves of 95% at 5 years, 70-90% at 10 
years and 50-80% at 15 years23. 
A number of factors may influence the relative durability of surgical and trans-catheter valves. 
Valve tissue damage during loading, lack of routine anti-calcification treatment in first-generation 
devices, and incomplete and eccentric frame expansion might all potentially lead to worse long-
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term durability for trans-catheter valves24. In contrast, the increased effective orifice area of the 
TAVI valve, particularly with supra-annular prostheses, and reduced incidence of patient 
prosthesis mismatch may confer a significant advantage with respect to durability.25 Current 
data suggest trans-catheter valve durability is comparable to surgical valve durability in the short 
to medium term, but long term data are lacking.  
 
Comparison of CoreValve and Edwards prostheses 
We found excellent overall long-term durability with both the CoreValve and Edwards 
prostheses, with only 1 case of severe SVD with CoreValve and none with Edwards, and no 
difference in the incidence of moderate SVD. However, the CoreValve device was associated 
with a reduction in peak gradient over time. In addition, there appeared to be an improvement in 
paravalvular AR with  
Corevalve, with a significant increase in the number of patients with none or trivial leak. Both of 
these findings may be explained by long-term continued expansion of the self-expanding nitinol 
frame of the CoreValve. Nonetheless, these data are not randomized, involve a relatively small 
number of patients, and should be considered hypothesis-generating only. 
 
STUDY LIMITATIONS  
Echocardiographic follow up data were only available in those patients who were still alive 
and/or in whom late echocardiographic follow-up data were available before death, and this was 
only 15.8% of all patients who underwent TAVI in the contributing centres between 2007-2011. 
A significant proportion of those patients without long-term echo data were dead, with the cause 
of death being uncertain in the majority of patients. We cannot exclude death due to SVD in 
some of these patients. 
 13 
Follow-up echo data were obtained from standard clinical follow-up scans rather than dedicated 
research studies, and as a consequence complete dataset were not available in all cases, 
Hence, some analysis may have been affected by missing variables.  
Median follow-up was only 5.8 years, with fewer than 15% having follow up beyond 8 years. 
Longer-term data are needed for more robust analysis; we plan to continue follow-up of this 
study cohort and report annually on valve durability.  
Finally, only first-generation of TAVI valves were used during the study period, and operator 
experience was limited.  
 
 
CONCLUSIONS 
Long-term TAVI valve function after TAVI was excellent, with no increase in gradient or 
regurgitation at a median follow-up of 5.8 years, up to a maximum of 10 years, and severe 
structural valve degeneration in less than 0.5% of patients.  
 
PERSEPECTIVES 
 
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: Severe Structural valve 
degeneration is uncommon in patients undergoing TAVI, with excellent long term outcomes.  
 
TRANSLATIONAL OUTLOOK: Further research should be directed toward understanding the 
mechanisms of structural valve degeneration, and its relationship to long term outcomes in 
patients undergoing TAVI.  
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Figure Legends 
 
Figure 1: Severity of aortic regurgitation at baseline and follow up according to valve type 
Figure 2: Boxplot of peak gradient at baseline and follow-up by valve type  
Figure 3: Kaplan-Meier curve demonstrating freedom from structural valve degeneration over 
time  
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Table 1: Baseline characteristics of study population 
Male (n/N, %) 126/235 (54%) 
Age (mean ± SD)  79.3±7.47 
Logistic Euroscore (mean ±SD) 19.7±12.3 
Prior cardiac surgery 93/224 (41.5%) 
Pulmonary disease 60/163 (26.9%) 
Previous stroke/TIA 43/181 (19.2%) 
Peripheral vascular disease 60/235 (25.5%) 
Creatinine > 200 μmol/l  11/224 (4.9%) 
Atrial fibrillation 55/220 (25.0%) 
Previous MI 60/235 (25.5%) 
Diabetes mellitus  52/224 (23.2%) 
Peak gradient (mean±SD)  80.6±26.2 
Aortic valve area (mean±SD)  0.69±0.3 
Left ventricular function  
 Normal (LVEF ≥50%) 163/235 (69.4%) 
 Moderately impaired (30-49%) 52/235 (22.1%) 
 Severely impaired (<30%) 20/235 (8.5%) 
PA pressure >60mmHg 39/235 (16.6%) 
Annulus diameter (mean ±SD; mm)  23.4, (22.7±2.3) 
Data are presented as n/total number (percent). Denominators vary due to some missing data.  
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Table 2: Procedural Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Anaesthesia, % 173/235 (73.6%) 
Access, %   
 Trans-femoral 180/224 (80.36%) 
 Trans-apical 31/224 (13.8%) 
 Subclavian 8/224 (3.6%) 
 Transaortic 5/224 (2.2%) 
Valve Type   
                              SAPIEN 45/234 (19.2%) 
                              SAPIEN XT 35/234 (15%) 
                              Core Valve 150/234 (64.1%) 
                              Portico 4/234 (1.7%) 
Pre-dilatation (BAV) 214/235 (91.1%) 
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Table 3: In hospital outcomes  
 
 
Successful valve deployment 229/235 (97.4%) 
AR grade (echo or fluoro)   
                                        None/Mild 193/213 (90.6%) 
                                        Moderate 20/213 (9.4%) 
                                        Severe 0/213 (0%) 
Major vascular complications  4/234 (1.7%) 
Stroke 5/234 (2.1)% 
New permanent pacemaker  39/222 (17.6%) 
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Table 4: Baseline vs Follow-up Echocardiographic Data for all valves  
 Baseline Follow up P 
Peak gradient*  19.4 (18.1 – 20.6) 17.2 (15.8– 18.6) 0.003 
Aortic regurgitation     
None/Trivial 70/213 (32.9%) 110/230 (47.8%) 0.055 
 Mild 123/213 (57.7%) 96/230 (41.7%) 0.01 
 Moderate 20/213 (9.4%) 23/230 (10%) 0.95 
 Severe 0/213 (0%) 1/230 (0.45%) - 
LV function      
 Normal 186/218 (85.3%) 187/221 (84.6%) 0.83 
 Moderately impaired 20/218 (9.2%) 22/221 (10%) 0.94 
Severely impaired 12/218 (5.5%) 12/221 (5.4%) 0.99 
*Data are mean (95% confidence interval); p values are from t-tests for continuous variables or 
from a two-sample test of proportions 
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Table 5: Baseline vs Follow-up Echocardiographic data according to valve type 
 
 SAPIEN/XT 
Baseline 
SAPIEN/XT 
Follow-up  
 
P 
CoreValve 
Baseline  
CoreValve 
Follow-up  
 
P 
Peak gradient* 19.3 (17.2 – 
21.3)  
20.5 (17.6 – 
23.3) 
0.2
9 
19.2 (17.7 – 
20.8) 
15.3 (13.9–16.8) <0.000
1 
None/Trivial 
AR 
37/68 
(54.4%) 
37/69 
(53.6%) 
0.8
4 
30/136 
(22.1%) 
69/149 (46.3%) 0.02 
Mild AR 22/68 
(32.3%) 
23/69 
(33.3%) 
0.9
7 
95/136 
(69.9%) 
66/149 (44.3%) 0.001 
Moderate AR 9/68 (13.2%) 9/69 
(13.04%) 
0.9
9 
11/136 
(8.1%) 
13/149 (8.7%) 0.96 
Severe AR 0/68 (0%) 0/69 (0%) NS 0/136 (0%) 1/149 (0.7%) NS 
*Data are mean (95% confidence interval); p values are from t-tests for continuous variables or 
from a two-sample test of proportions 
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Figure 1 
Severity of aortic regurgitation at baseline and follow up according to valve type 
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Figure 2  
Box and whisker plot with its IQR divided by the median and Tukey-style whiskers which extend 
to a maximum of 1.5 × IQR beyond the box. The dots beyond the whiskers represent outliers. 
No difference in peak gradient (mmHg) in SAPIEN/XT system over time (19.3 v 20.5, p=0.484). 
Significant changes in peak gradient for Core Valve/Evolut system 19.3 vs 15.2 mmHg, 
p<0.0001.  
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Figure 3 
Kaplan-Meier curve demonstrating freedom from structural valve degeneration over time 
 
 
 
 
 
 
